NILOOFAR KALANTARI: Open Payments
NPI 1427738962 · MISSION HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,859 in 85 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $2,187 · 2025 $2,859
Food & beverage: $2,749Education: $110
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 10 | $679 |
| Janssen Biotech, Inc. | 12 | $506 |
| Arcutis Biotherapeutics, Inc. | 6 | $316 |
| ABBVIE INC. | 9 | $264 |
| UCB, Inc. | 8 | $257 |
| Paratek Pharmaceuticals, Inc. | 8 | $206 |
| Novartis Pharmaceuticals Corporation | 11 | $193 |
| GENZYME CORPORATION | 6 | $147 |
| Lilly USA, LLC | 3 | $81 |
| Incyte Corporation | 3 | $60 |
Products named: NEMLUVIO, TREMFYA, Zoryve, Bimzelx, NUZYRA, COSENTYX, DUPIXENT, BOTOX.
Industry payments across CA — which companies pay providers there.
